Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MeAxon AT is an oral nutraceutical formulation developed by Bion Therapeutics for the management of various metabolic disorders. It is part of the company's Pharma Wellness product line, which targets conditions such as neurodegenerative disorders, movement disorders, muscle cramps, chronic fatigue syndrome, cardiac myopathy, non-alcoholic fatty liver disease, and male infertility. While the exact composition of the AT variant is not publicly specified, it belongs to a product family typically characterized by B-vitamins and metabolic cofactors like methylcobalamin and benfotiamine, intended to address nutritional gaps and support metabolic health in patients with chronic metabolic conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MeAxon AT.